AI
Sunday, January 19, 2025 12:33:55 AM
I have something interesting and your insight will be appreciated. TBH, I think the facility might be related to DCVax-L. Did you see directors from Amgen liked the linkedin posts of Oncovir's employee.
Here is a large biologic manufacturing facility that Amgen started to construct in September 2021. The construction was completed in February 2024. Amgen said the facility will be used primarily for filling, labelling and packaging a wide variety of pharmaceuticals in vials and syringes. The company claimed that the 300,000 square feet manufacturing facility was completed in 26 months and made it the most rapid site completion in Amgen's nearly 45-year history. I bet Amgen must have adopted crazy working hours like Merck. But I simply cannot see from Amgen's 10k which product would make Amgen to finish a massive building in such a big hurry. Can you spot the revenue increase of any product that can push Amgen to finish the facility in the most rapid speed?
As you can see that CRB Group was responsible for design services. Seems to me CRB Group can provide comprehensive service on manufacturing facilities for cell therapy.
You claimed that you read hundreds of peer-review papers. Enlighten me if VEGF can replace BCG to help dendritic cell maturation. Dmitry Gabrilovich even wrote a paper about this last century. The reason I ask about this is that Amgen has VEGF inhibitor. I assume you would agree that Dr. Vivek Subbiah should be the one who helped $NWBO on the BCG replacement.
https://journals.aai.org/jimmunol/article/160/3/1224/31012
https://www.amgen.com/stories/2024/02/amgen-goes-oh-io-with-opening-of-newest-manufacturing-facility
Amgen first announced plans to build the Amgen Ohio facility in June 2021. Construction of the site took 26 months from groundbreaking to approval by the Food and Drug Administration (FDA) in January 2024 – making it the most rapid site completion in Amgen's nearly 45-year history. This new facility is the latest step in a planned expansion of Amgen's U.S. based manufacturing capabilities – another facility is currently under construction in North Carolina.
Etanercept, sold under the brand name Enbrel among others, is a biologic medical product that is used to treat autoimmune diseases by interfering with tumor necrosis factor, a soluble inflammatory cytokine, by acting as a TNF inhibitor.
Denosumab, sold under the brand names Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss.
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.
Otezla® is a pill that helps treat some symptoms of plaque psoriasis, psoriatic arthritis, and oral ulcers in BD. In 2019, Amgen acquired Otezla from Celgene for $13.4 billion. In 2020, Otezla generated $2.2 billion for Amgen.
XGEVA is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
Aranesp is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease.
Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor.
Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.
https://www.packaging-gateway.com/projects/amgens-assembly-and-packaging-facility-new-albany-ohio-us/?cf-view
Turner Construction, a construction management company based in the US, is the lead contractor for the project’s construction. CRB Group, a sustainable engineering, architecture and consulting company based in the US, is responsible for providing design services.
https://www.crbgroup.com/biotechnology/cell-gene-therapy
https://www.crbgroup.com/news/news-2021/bream-and-salzmann-featured-in-bioprocess-international
2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
https://www.nature.com/articles/s41698-024-00563-4
V.S. reports research funding/grant support (to institution) for conducting clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, Inc., NanoCarrier, Co., National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, and Vegenics Pty Ltd.
2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
https://aacrjournals.org/cancerdiscovery/article/13/9/2012/728854
V. Subbiah reports grants from Relay Therapeutics, Inc. during the conduct of the study; research funding/grant from Relay Therapeutics, Inc. for clinical trial research support; support for clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GSK, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, Inc., NanoCarrier, Co., the National Comprehensive Cancer Network, the NCI-Cancer Therapy Evaluation Program, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Inc., Roche/Genentech, Takeda, Turning Point Therapeutics, The University of Texas MD Anderson Cancer Center, and Vegenics Pty Ltd.
2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
https://aacrjournals.org/clincancerres/article/28/13/2762/704976/Antitumor-Activity-of-Lurbinectedin-a-Selective
V. Subbiah reports grants from PharmaMar during the conduct of the study. V. Subbiah also reports grants from PharmaMar, Eli Lilly/LOXO Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals, and Helsinn Pharmaceuticals; clinical trial research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berg Health, Incyte, Fujifilm, D3, Pfizer, MultiVir, Amgen, AbbVie, Alfasigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, PharmaMar, and Medimmune;
2021
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
https://aacrjournals.org/mcr/article/19/3/395/271907/Molecular-Profiling-of-Metastatic-Bladder-Cancer
V. Subbiah reports grants from Incyte during the conduct of the study; and Vivek Subbiah, Research funding/grant support for clinical trials: FUJIFILM Pharmaceuticals U.S.A., Inc., Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Pharmamar, D3, Pfizer, Multivir, Amgen, AbbVie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, LOXO Oncology, Medimmune, Altum, Dragonfly therapeutics, Takeda and Roche/Genentech, National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center.
2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
https://aacrjournals.org/mct/article/19/5/1165/92857/Genomics-Morphoproteomics-and-Treatment-Patterns
V. Subbiah is a consultant/advisory board member at LOXO Oncology/Eli Lilly, Helsinn, R-Pharma US, Incyte, QED, Novartis, Medimmune and reports receiving a commercial research grant from LOXO Oncology/Eli Lilly, Blueprint Medicines, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, ABBVIE, Agensys, Boston Biomedical, Idera, Turning Point therapeutics, Exelixis, Inhibrx, Altum, Medimmune, Dragonfly Therapeutics, Takeda, Roche/Genentech, Novartis, Bayer, GSK, Nanocarrier, Berghealth, Incyte, and Northwest Biotherapeutics.
2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial
https://aacrjournals.org/clincancerres/article/25/13/3802/81876/Alpha-Particle-Radium-223-Dichloride-in-High-risk
V. Subbiah reports receiving commercial research grants from Bayer, Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Multivir, Blueprint Medicines, LOXO Oncology, Vegenics, Alfasigma, Agensys, Idera Pharma, Boston Biomedical, Inhibrx, and Exelixis, and is a consultant/advisory board member for MedImmune/Astra Zeneca.
2018
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers
https://aacrjournals.org/clincancerres/article/24/16/3845/277824/Cytokines-Produced-by-Dendritic-Cells-Administered
V. Subbiah reports receiving commercial research grants from AbbVie, Amgen, Bayer, BERG, Blueprint Medicines, D3, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Loxo Oncology, MultiVir, NanoCarrier, Northwest Biotherapeutics, Novartis, Pfizer, PharmaMar, and Vegenics.
2017
Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
https://www.mdpi.com/2075-4418/7/1/10https://academic.oup.com/oncolo/article/22/8/881/6444413
Vivek Subbiah receives research funding for clinical trials from Novartis, Bayer, GSK, Nanocarrier, Vegenics, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Bluprint medicines and Roche/ Genentech.
2016
Universal Genomic Testing Needed to Win the War Against CancerGenomics IS the Diagnosis
https://jamanetwork.com/journals/jamaoncology/article-abstract/2513253
Dr Subbiah reports research funds from Novartis, Bayer, GSK, Nanocarrier, Vegenics, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm
